Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
35 hedge funds and large institutions have $108M invested in Sinovac Biotech, Ltd in 2017 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 13 reducing their positions, and 8 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 38 → 35 (-3)
15% less capital invested
Capital invested by funds: $128M → $108M (-$19.8M)
31% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 13
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$15.7M |
| 2 |
Renaissance Technologies
New York
|
+$896K |
| 3 |
GP
GLG Partners
London,
United Kingdom
|
+$525K |
| 4 |
Two Sigma Investments
New York
|
+$437K |
| 5 |
Millennium Management
New York
|
+$323K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$31.9M |
| 2 |
USAA
United Services Automobile Association
San Antonio,
Texas
|
-$2.04M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$402K |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$157K |
| 5 |
FIM
Freedom Investment Management
Hartford,
Connecticut
|
-$111K |
SVA Hedge Fund Activity: Q1 2017 in Review
35 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q1 2017, worth a combined $108M — down 15% from $128M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of SVA and 5 opened new positions — a net loss of 3 holders — while 13 trimmed existing stakes and 9 added.
The largest buyer was Morgan Stanley, adding an estimated $15.7M. The largest seller was Wellington Management Group, cutting an estimated $31.9M.
- 35 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q1 2017, down from 38 in Q4 2016.
- Funds reported $108M of Sinovac Biotech, Ltd stock for Q1 2017, down 15% quarter-over-quarter.
- 5 funds opened new Sinovac Biotech, Ltd positions in Q1 2017 and 8 closed out, a net change of -3 holders.
- The largest Sinovac Biotech, Ltd buyer in Q1 2017 was Morgan Stanley, an estimated $15.7M added.
- The largest Sinovac Biotech, Ltd seller in Q1 2017 was Wellington Management Group, an estimated $31.9M sold.
Based on aggregated 13F filings for Q1 2017.